www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/11045

Title: Considerations for Comparing a Test Drug With Standard of Care in Phase 2 Clinical Trials of Central Nervous System Disorders
Authors: Mallinckrodt, Craig H.
Detke, Michael J.
Prucka, William R.
Ruberg, Stephen J.
MOLENBERGHS, Geert
Issue Date: 2010
Publisher: DRUG INFORMATION ASSOC
Citation: DRUG INFORMATION JOURNAL, 44(4). p. 443-452
Abstract: An increasing need exists to understand the benefits of a test drug compared with standard of care (SoC) earlier in development. Even if a drug is superior to placebo, it may not be worthwhile to continue development unless it has advantages over SoC. However, efficacy and safety comparisons versus SoC in early phase studies can be challenging. Analytic studies were conducted to illustrate that in common scenarios simply randomizing a few patients to SoC will frequently yield misleading results. It may take samples sizes at least fivefold greater to achieve reliable comparisons of a test drug with SoC than when comparing versus placebo. Therefore, it is important that the rate of false positive and false negative results be quantitatively evaluated before determining the sample size and the criteria upon which the test drug and SoC will be compared. Because test drugs often have no benefit, comparing a test drug with SoC may unnecessarily use resources that could be devoted to investigating other drugs. Moreover, it can be difficult to construct valid comparisons of a test drug versus SoC without experience with the test drug regarding appropriate dosing, patient population, and so on. An example with actual clinical trial data is used to illustrate how the trade-off between the need and the difficulties in comparing a test drug with SoC in phase 2 can be mitigated using a literature database of placebo-controlled studies to construct a historical comparison.
Notes: [Mallinckrodt, Craig H.; Prucka, William R.; Ruberg, Stephen J.] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA. [Detke, Michael J.] MedAvante, Hamilton, NJ USA. [Detke, Michael J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Detke, Michael J.] McLean Hosp, Dept Psychiat, Belmont, MA 02178 USA. [Detke, Michael J.] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA. [Molenberghs, Geert] Hasselt Univ, Diepenbeek, Belgium. [Molenberghs, Geert] Katholieke Univ Leuven, Leuven, Belgium. cmallinc@lilly.com
URI: http://hdl.handle.net/1942/11045
ISI #: 000279705600008
ISSN: 0092-8615
Category: A1
Type: Journal Contribution
Validation: ecoom, 2011
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
artikel82.78 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.